STATE STREET CORP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 97 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
STATE STREET CORP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$2,386,958
-12.7%
2,022,846
+4.3%
0.00%
Q2 2023$2,733,584
+316.5%
1,938,712
+343.1%
0.00%
Q1 2023$656,244
-35.9%
437,496
-50.0%
0.00%
Q4 2022$1,023,740
+106.0%
874,992
+98.8%
0.00%
Q3 2022$497,000
-28.5%
440,0960.0%0.00%
Q2 2022$695,000
-78.6%
440,096
-79.1%
0.00%
Q1 2022$3,242,000
-36.2%
2,105,107
+1.5%
0.00%
Q4 2021$5,082,000
-63.1%
2,074,234
-62.0%
0.00%
-100.0%
Q3 2021$13,755,000
+158.4%
5,458,451
+192.2%
0.00%
Q2 2021$5,324,000
+3357.1%
1,868,046
+2745.3%
0.00%
Q1 2021$154,000
+51.0%
65,654
+12.9%
0.00%
Q4 2020$102,000
+88.9%
58,1540.0%0.00%
Q3 2020$54,000
+5.9%
58,1540.0%0.00%
Q2 2020$51,000
-96.5%
58,154
-96.7%
0.00%
Q1 2020$1,452,000
-9.2%
1,753,991
-2.4%
0.00%
Q4 2019$1,600,000
-7.9%
1,797,923
+1.4%
0.00%
Q3 2019$1,738,0001,773,9070.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$55,198,0004.16%
Raffles Associates 1,930,536$3,050,0003.32%
Defender Capital, LLC. 5,131,935$8,108,0003.18%
Prescott General Partners LLC 1,851,851$2,926,0000.20%
DAFNA Capital Management LLC 140,000$221,0000.06%
Laurion Capital Management LP 2,422,367$3,827,0000.06%
Beirne Wealth Consulting Services, LLC 45,000$71,0000.05%
Fort Sheridan Advisors LLC 78,931$125,0000.04%
Long Focus Capital Management, LLC 215,000$340,0000.04%
MORGAN JESS S & CO INC 20,000$32,0000.03%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders